

Parque Tecnológico Cartuja ' 93.  
Avda Thomas A. Edison No. 7  
E - 41092 SEVILLA. SPAIN.  
Phone: + 34.954 460553  
Fax: + 34. 954 460145  
E-mail: [solicitudescna@us.es](mailto:solicitudescna@us.es)

## **Access to the Centre diagnostic image of Centro Nacional de Aceleradores (CDI-CNA) for performing of clinical studies**

The national accelerators Centre offers to the biomedical community the use of its PET-CT scanner, whose characteristics are indicated in the technical annex. The purpose of the PET-CT of the CNA is the development of the research and the realization of studies in Clinical Oncology, Neurology, cardiology and other areas requiring the molecular imaging technology.

1. Use of PET-CT applications will be sent to the national centre of accelerators ([solicitudescna@us.es](mailto:solicitudescna@us.es)), according to the model available on the following [link](#). Such applications must include among others:
  - 1.1. The name of the researcher responsible for the proposal.
  - 1.2. Justification of the scientific interest of the proposal, specifying publications and projects that support the ability of the team.
  - 1.3. Details of the research project financing proposal.
  - 1.4. Listing of patients who will participate in the project.
  - 1.5. Need of the medical personnel, physician, nurse or technician to perform the study.
  - 1.6. Statement of the researcher that he has the approval of the relevant Ethics Committee for research, as well as the informed consent of patients, which is explicitly authorized the use of the images for presentation or publication with scientific purposes.
  - 1.7. Billing data.
2. Applications will be evaluated by the Scientific Committee of the ANC, and, once approved, will be allocated the days needed to carry out the proposal.
3. Applicants may require the collaboration of the health staff the Virgen del Rocío Hospital, linked to the Diagnostic Centre for Image of the CNA under the specific agreement.

4. Rates of use of installation will be established according to the characteristics of the study to be carried out. For more complex tests, the utilization rate is amended according to the request.
5. Medical staff of the HUVR involved in the conduct of clinical trials shall be deemed part of the team, for the purpose of financing of the staff, and publications.
6. The radiopharmaceuticals will be provided by Curium Pharma, or for the radiopharmacy unit of the CNA. The following commercial drugs are currently available for use: [ $^{18}\text{F}$ ]FDG, [ $^{18}\text{F}$ ]FDOPA, [ $^{18}\text{F}$ ] Fluoromethylcholine, [ $^{18}\text{F}$ ]Florbetaben and the following research ones: [ $^{18}\text{F}$ ]FMISO, [ $^{18}\text{F}$ ]FLT and [ $^{18}\text{F}$ ]NaF.

In Seville, October 11, 2017

Prof. Joaquín José Gómez Camacho

Director of Centro Nacional de Aceleradores